Qualitative Findings

By Casey Ferrell, Senior Research Analyst Our recent survey of pharma companies revealed that 58 percent have dedicated digital marketing groups. I think it’s safe to assume at this point that the digital revolution is real and is only going to continue...

By Eric Bolesh, Director of Research In collaborations among pharmaceutical and biotech companies, conflicts inevitably arise — and they can spring from a host of different factors. Here are several of the most common issues that we hear about in...

By Shaylyn Pike, Senior Research Analyst Pharmaceutical companies' global clinical development strategies are diverse, but there are some points of agreement: clinical trials in emerging markets are more successful when companies hire local expertise....

By David Richardson, Research Team Leader Post-marketing research is a growth area. An ever more cautious and stringent regulatory environment, payers that require more and more data to justify formulary approval and reimbursement, and more crowded...

By Stephanie Swanson, Strategic Marketing Manager The CEI research team is launching two new benchmarking studies that will explore the value proposition, Return-on-Investment and performance measurement of the Medical Science Liaison function. Early...

By Eric Bolesh, Director of Research When we spoke with teams to complete our recent examination of companion diagnostics (CDx) development, we heard a lot about the difficulties of the partnering process. It’s a difficult road for all parties, as choosing...

By Michelle Vitko, Senior Research Analyst In an earlier blog post, I discussed the cost of patient non-adherence -- poorer health outcomes for patients and billions of dollars in lost product revenue. Low adherence rates have been a problem for a...

By Elio Evangelista, Director of Research The promise of adaptive clinical trials leading to significant cost savings is attractive, and many drug companies have already put the strategy into practice. But most times, companies implement adaptive clinical...

By Shaylyn Pike, Senior Research Analyst The managed markets function in the United States has been around for many years. Since the arrival of Medicare, Medicaid and the health insurance industry in its current form, drug and device companies have...

By Ryan McGuire,Senior Research Analyst The megatrend of personalized medicine gained a significant boost of adrenaline recently as Vertex Pharmaceutical's cystic fibrosis drug, Kalydeco (ivacaftor), earned FDA approval. As with much of personalized medicine's...